Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors inside the central anxious method, conolidine modulates alternate molecular targets. A Science Advancements review observed that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://vannevark628fsg9.blog4youth.com/profile